Schepens Eye Research Institute - Click to return to home page

Andrius Kazlauskas

Current Publications

Click here for a PubMed list of abstracts formatted by BioMed Central

Signaling

  1. Rosenkranz, S., DeMali, K.A., Gelderloos, J.A., Bazenet, C., Kazlauskas, A.   Identification of the receptor-associated signaling enzymes that are required for platelet-derived growth factor-AA-dependent chemotaxis and DNA synthesis. J Biol Chem. 1999; 274: 28335-28343.

  2. Jones, S.M., Klinghoffer, R., Prestwich, G.D., Toker, A., Kazlauskas, A.   PDGF induces an early and a late wave of PI 3-kinase activity, and only the late wave is required for progression through G1.   Current Biology 1999; 9:512-521.

  3. Balciunaite, E., Jones, S., Toker, A., Kazlauskas, A.   PDGF initiates two distinct phases of protein kinase C activity that make unequal contributions to the G0 to S transition.   Current Biology 2000; 10: 261-267.

  4. Rosenkranz, S., Ikuno, Y., Leong, F.L., Klinghoffer, R.A., Miyake, S., Band, H., Kazlauskas, A.   Src family kinases negatively regulate platelet-derived growth factor receptor-dependent signaling and disease progression. J. Biol. Chem. 2000; 275: 9620-9627.

  5. Jones, S. M., Kazlauskas, A.   Growth factor-dependent mitogenesis requires two distinct phases of signalling.   Nature Cell Biol. 2001; 3: 165-172.  

  6. Lei H, Kazlauskas A. Growth factors outside of the PDGF family employ ROS/SFKs to activate PDGF receptor alpha and thereby promote proliferation and survival of cells. J Biol Chem. 2009; 284: 6329-36.

Proliferative Vitreoretinopathy (PVR)

  1. Andrews, A., Balciunaite, E., Leong, F.L., Tallquist, M., Soriano, P., Refojo, M., Kazlauskas, A.   Platelet-derived growth factor plays a key role in proliferative vitreoretinopathy.   IOVS, 1999; 40:2683-2689.

  2. Ikuno, Y., Leong, F. L., Kazlauskas, A.   Attenuation of experimental proliferative vitreoretinopathy by inhibiting the PDGF receptor.   Invest. Ophthalmol. Vis. Sci.   2000; 41: 3107-3116.

  3. Lei H, Hovland P, Velez G, Haran A, Gilbertson D, Hirose T, Kazlauskas A. Potential role for PDGF-C in experimental and clinical proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 2007; 48: 2335-42.

  4. Lei H, Velez G, Hovland P, Hirose T, Kazlauskas A. Plasmin is the major protease responsible for processing PDGF-C in the vitreous of patients with proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 2008; 49: 42-48.

  5. Cui J, Lei H, Samad A, Basavanthappa S, Maberley D, Matsubara J, Kazlauskas A. PDGF receptors are activated in human epiretinal membranes. Exp Eye Res. 2009; 88: 438-44.

  6. Lei H, Hovland P, Velez G, Gilberston D, Hirose T, Kazlauskas A. Growth factors outside of the PDGF family drive experimental PVR. Invest Ophthalmol Vis Sci. 2009; 50: 3394-403.

Endothelial Dysfunction in Diabetes

  1. Lei H, Romeo G, Kazlauskas A.   Heat Shock Protein 90 a Dependent Translocation of Annexin II to the Surface of Endothelial Cells Modulates Plasmin Activity in the Diabetic Rat Aorta.   Circ. Res. 2004; 94:902-9.

  2. Romeo G, Frangioni JV, Kazlauskas A.   Profilin acts downstream of LDL to mediate diabetic endothelial cell dysfunction.   FASEB J. 2004; 18: 725-7.

  3. Romeo GR, Moulton KS, Kazlauskas A. Attenuated expression of Profilin-1 confers protection from atherosclerosis in the LDL receptor-null mouse. Circ. Res. 2007; 101: 357-67.

  4. Romeo GR, Kazlauskas A. Oxysterol and diabetes activate STAT3 and control endothelial expression of profilin-1 via OSBP1. J. Biol. Chem. 2008; 283: 9595-605. 

Angiogenesis

  1. Im E, Venkatakrishnan A, Kazlauskas A. Cathepsin B Regulates the Intrinsic Angiogenic Threshold of Endothelial Cells. Mol Biol Cell. 2005; 16:3488-3500.

  2. Im E, Kazlauskas A. Regulating angiogenesis at the level of PtdIns-4,5-P(2). EMBO J. 2006; 25: 2075-82.

  3. Im E, Kazlauskas A. SFKs promote vessel stability by antagonizing the Rho/ROCK pathway. J. Biol. Chem. 2007; 282: 29122-9.

Reviews

  1. 1. Rosenkranz, S., Kazlauskas, A.   Evidence for distinct biological properties and signaling machineries of the PDGF receptor a and b subtypes.   Growth Factors, 1999; 16:201-216.

  2. DeMali, K.A., Godwin, S.L., Soltoff, S.P., Kazlauskas, A.   Multiple roles for Src in a PDGF-Stimulated Cell.   Experimental Cell Research, 1999; 253:271-279.

  3. Ikuno, Y., Kazlauskas, A.   Recent progress in gene therapy for eye diseases.   Gene Therapy and Molecular Biology, 1999; 4:203-208.

  4. Jones SM, Kazlauskas A. Connecting signaling and cell cycle progression in growth factor-stimulated cells. Oncogene 2000; 19:5558-67.

  5. Tallquist M, Kazlauskas A.  PDGF signaling in cells and mice. Cytokine and Growth Factor Reviews 2004; 15: 205-13.

  6. Kazlauskas A. The priming/completion paradigm to explain growth factor-dependent cell cycle progression. Growth Factors 2005; 23: 203-10.

  7. Im E, Kazlauskas A. New insights regarding vessel regression. Cell Cycle 2006; 5: 2057-59.

  8. Im E, Kazlauskas A. The role of cathepsins in ocular physiology and pathology. Exp Eye Res. 2006; 84: 383-8.

  9. Im E, Kazlauskas A. PtdIns-4,5-P2 as a potential therapeutic target for pathologic angiogenesis. Expert Opin Ther Targets 2007; 11: 443- 51.

  10. Lei H, Kazlauskas A. Focus on molecules: platelet-derived growth factor C, PDGF-C. Exp. Eye Res 2007; 86: 711-2.

  11. Motiejunaite R, Kazlauskas A. Pericytes and ocular diseases. Exp. Eye Res. 2008; 86: 171-7.

SEO by Artio